DHGWA
NBIX icon

Dixon Hughes Goodman Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$0 Sell
5
-19
-79% -$1.61K ﹤0.01% 1009
2021
Q4 		$2K Buy
+24
New +$2.21K ﹤0.01% 684

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's NBIX Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors reduced its Neurocrine Biosciences (NBIX) stake by 79% in Q1 2022, selling an estimated $1.61K and leaving 5 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1009.

Dixon Hughes Goodman Wealth Advisors first reported a position in NBIX in Q4 2021 and has held it in 2 quarters since. The position peaked at $2K in Q4 2021. 426 funds tracked by Wall St. Rank hold NBIX as of Q1 2022.

  • Dixon Hughes Goodman Wealth Advisors held 5 shares of Neurocrine Biosciences worth $0 as of Q1 2022.
  • Dixon Hughes Goodman Wealth Advisors sold 19 Neurocrine Biosciences shares in Q1 2022, an estimated $1.61K.
  • Neurocrine Biosciences made up ﹤0.01% of Dixon Hughes Goodman Wealth Advisors's portfolio in Q1 2022, its #1009 holding.
  • Dixon Hughes Goodman Wealth Advisors first reported a position in Neurocrine Biosciences in Q4 2021 and has held it in 2 quarters since.
  • Dixon Hughes Goodman Wealth Advisors's Neurocrine Biosciences position peaked at $2K in Q4 2021.
  • 426 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.